Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes degradation of low-density lipoprotein receptor (LDLR) and plays a central role in regulating plasma levels of LDL cholesterol levels, lipoprotein(a) and triglyceride-rich lipoproteins, increasing the risk of cardiovascular disease. Addi...
Main Authors: | Xiao-dan Xia, Zhong-sheng Peng, Hong-mei Gu, Maggie Wang, Gui-qing Wang, Da-wei Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-10-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.764038/full |
Similar Items
-
Correlation of PCSK9 and Serum sdLDL Levels and Other Demographic and Laboratory Indicators in Healthy Individuals
by: Reza Hosseini-Fard, et al.
Published: (2018-05-01) -
PCSK9 as an Atherothrombotic Risk Factor
by: Tadeja Sotler, et al.
Published: (2023-01-01) -
PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01) -
<i>Acanthaster planci</i> Inhibits PCSK9 and Lowers Cholesterol Levels in Rats
by: Nurjannatul Naim Kamaruddin, et al.
Published: (2021-08-01) -
The Association of Proprotein Convertase Subtilisin/Kexin Type 9 to Plasma Low-Density Lipoproteins: An Evaluation of Different Methods
by: Laura Canclini, et al.
Published: (2021-12-01)